

DRUG PROFILE
**NEWER ANTIBIOTICS -
USE IN PEDIATRIC PRACTICE**

***Jeeson C Unni**
** **Ranjit Baby Joseph**

Abstract: *There are few trials assessing the use of newer antibiotics in the neonates and children. The reality strikes that 50 times more studies are being conducted in adults than in children; 177 and 580 times more in adults than in neonates and preterm babies, respectively. Though there are 2-5 new drugs being introduced for each group of antibiotic, only 2 antibiotics - carbavance and solithromycin - have been investigated in 1 and 2 ongoing clinical trials respectively in pediatric patients.*

Keywords: *Newer antibiotics, Drug resistance, Pediatric trials.*

Points to Remember

- *About 41 new antibiotics are in development.*
- *Only about 60% of drugs that enter phase III end up getting approval and based on the pipeline analysis is very clear that there are not enough new drugs that are available to patients.*
- *Although the bacterial resistance is developing rapidly newer antibiotics in pipeline provides us some hope; and we need more research in this regard in neonates, children and adolescents.*
- *Judicious use of the antibiotics is the need of the hour to present rapid development of extensive drug resistance.*

References

1. Chemical Sciences Roundtable; Board on Chemical Sciences and Technology; Division on Earth and Life Studies; National Research Council. Technological Challenges in Antibiotic Discovery and Development: A Workshop Summary. Washington (DC): National Academies Press (US); 2014 Jan 27. 2, Challenges In Overcoming Antibiotic Resistance. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK200811/>. Accessed on 10th May, 2019.
2. Infectious Diseases Society of America. The 10x'20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020. Clin Infect Dis 2010; 50:1081-1083.
3. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharmacol therapeut 2015; 40(4):277-283.
4. Kallen AJ, Srinivasan A. Current epidemiology of multidrug resistant gram negative bacilli in the United States. Infect Control Hosp Epidemiol 2010; 31 Suppl 1: S51-54.
5. Thompson G, Barker CI, Folgori L, Bielicki JA, Bradley JS, Lutsar I, et al. Global shortage of neonatal and paediatric antibiotic trials: rapid review. BMJ Open 2017; 7(10):e016293.
6. Guidance for industry. Pediatric study plans: content of and process for submitting initial pediatric study plans and amended initial pediatric study plans. <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm360507.pdf>. Accessed on 6th May, 2019.

* Editor-in-Chief, IAP Drug formulary & Lead senior consultant - Pediatrics,

** Senior specialist - Pediatrics,
Aster Medcity, Kochi.

email: jeeson1955@gmail.com

7. Lutsar I. Often neglected: paediatric drug development - a regulatory and clinical view. Amsterdam, Netherlands, 2016. (S219 - Symposium lecture). Accessed on 12th May, 2019.
8. Cefepime. In: IAP Drug Formulary 2015. Eds. Jeesson CU. Nair MKC, Meon PSN, Bansal CP. A publication of Indian Academy of Pediatrics. Pixel Studio, Cochin 2015; pp267-268.
9. Meropenem. In: IAP Drug Formulary 2015. Eds. Jeesson CU. Nair MKC, Meon PSN, Bansal CP. A publication of Indian Academy of Pediatrics. Pixel Studio, Cochin 2015;p413.
10. Antibiotics review. 2011 Stanford School of Medicine. Accessed at <https://errolzodalg.com/medicine/pages/OtherPages/AntibioticReview.ChanuRhee.html> on 2/10/18. Accessed on 16th May, 2019.
11. Linezolid. In: IAP Drug Formulary 2015. Eds. Jeesson CU. Nair MKC, Meon PSN, Bansal CP. A publication of Indian Academy of Pediatrics. Pixel Studio, Cochin 2015;p400.
12. Dotis J, Losifidis E, Laonnidou M, Roilides E. Use of linezolid in pediatrics: a critical review. *Intl J Infect Dis* 2010; 14: e638-648.
13. Slover CM, Rodvold KA, Danziger LH. Tigecycline: a novel broad-spectrum antimicrobial. *Ann Pharmacother* 2007; 41(6):965-972.
14. Stutman HR. Clinical experience with aztreonam for treatment of infections in children. *Rev Infect Dis* 1991; 13(Suppl) 7:S582-585.
15. Yu Z, Qin W, Lin J, Fang S, Qiu J. Antibacterial mechanisms of polymyxin and bacterial resistance. *Biomed Res Int* 2015; 2015:679109.
16. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. *Annals of the Newyork Academy of Sciences*.<https://doi.org/10.1111/j.1749-6632.2011.06330.x>. Accessed on 16th May, 2019.
17. Kali A, Charles MV, Srirangaraj S. Cadazolid: A new hope in the treatment of Clostridium difficile infection. *Australas Med J* 2015; 8(8):253-262.
18. McCool R, Gould IM, Eales J, Barata T, Arber M, Fleetwood K, et al. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA. *BMC Infect Dis* 2017; 17(1):39.
19. Karageorgos SA, Miligkos M, Dakoutrou M, Tsioutis C. Clinical Effectiveness, Safety Profile, and Pharmacokinetics of Daptomycin in Pediatric Patients: A Systematic Review. *J Pediatr Infect Dis Soc* 2016; 5(4):446-457.
20. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, et al . New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. *Int J Antimicrob Agents* 2012; 39(2):96-104.
21. Messina JA, Fowler VG Jr, Corey GR. Oritavancin for acute bacterial skin and skin structure infections. *Expert Opin Pharmacother* 2015; 16(7):1091-1098.
22. Peng Z, Ling L, Stratton CW, Li C, Polage CR, Wu B, et al. Advances in the diagnosis and treatment of Clostridium difficile infections. *Emerg Microbes Infect* 2018; 7(1):15.
23. Politano AD, Sawyer RG. NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA. *Curr Opin Investig Drugs* 2010; 11(2):225-236.
24. Qin X, Huang H. Review of nemonoxacin with special focus on clinical development. *Drug Des Devel Ther* 2014; 8:765-774.
25. Bassetti M, Pecori D, Cojutti P, Righi E, Pea F. Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections, *Expert Opin Drug Metab Toxicol* 2017; 13(11):1193-1200.
26. Yoo BK, Triller DM, Yong CS, Lodise TP. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. *Ann Pharmacother* 2004; 38(7-8):1226-1235.
27. Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. *Ann Clin Microbiol Antimicrob* 2016; 15(1):34.
28. Comstock TL, Karpecki PM, Morris TW, Zhang JZ. Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis. *Clin Ophthalmol* 2010; 4:215-225.
29. Balbisi EA. Cefditoren, a new aminothiazolyl cephalosporin. *Pharmacotherapy* 2002; 22(10):1278-1293.
30. Corey A, So TY. Current Clinical Trials on the Use of Ceftaroline in the Pediatric Population. *Clin Drug Investig* 2017; 37(7):625-634.
31. Rodriguez BA, Giroto JE, Nicolau DP. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children. *Curr Pediatr Rev* 2018; 14(2):97-109.
32. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. *Clin Microbiol Rev* 2018; 31(2):e00079-17.
33. Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. *Infect Drug Resist* 2018; 11:1461-1472.
34. Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A,

- Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-â-Lactamase Inhibitor Combinations. *Drugs* 2018; 78(1):65-98.
35. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. *Drugs* 2007; 67(7):1027-1052.
 36. Kaushik A, Ammerman NC, Martins O, Parrish NM, Nuernberger EL. In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline Against Drug-Resistant Clinical Isolates of *Mycobacterium abscessus*. *Antimicrob Agents Chemother* 2019; 63(6):e00470-19.
 37. Vaishnavi C. Fidaxomicin—the new drug for *Clostridium difficile* infection. *Indian J Med Res* 2015; 141(4):398-407.
 38. Alirol E, Wi TE, Bala M, Bazzo ML, Chen XS, Deal C, Dillon JR, Kularatne R, et al. Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines. *PLoS Med* 2017; 14(7):e1002366.
 39. Figueira M, Fernandes P, Pelton SI. Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable *Haemophilus influenzae* and *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2016; 60(9):5533-5538.
 40. Paknikar SS, Narayana S. Newer antibacterials in therapy and clinical trials. *N Am J Med Sci* 2012; 4(11):537–547.
 41. Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. *Expert Rev Anti Infect Ther* 2012; 10(4):459-473.